Thoracic Surgery Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
Medical Oncology Department, Air Force Medical Center, PLA, Beijing, People's Republic of China.
Oncologist. 2024 Jun 3;29(6):543-545. doi: 10.1093/oncolo/oyad339.
Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.
对于表皮生长因子受体（EGFR）突变阳性的非小细胞肺癌（NSCLC）患者，序贯治疗方案可以克服酪氨酸激酶抑制剂（TKI）耐药性并最大程度地提高临床获益。在接受 EGFR-TKI 治疗一段时间后，晚期 NSCLC 患者可以实现出色的肿瘤控制。一旦肿瘤得到控制，患者可能会受益于其他局部治疗，例如手术或放射治疗。在这里，我们报告了一例晚期寡转移 NSCLC 伴 EGFR 突变患者的病例，该患者通过基于 EGFR-TKI 的精准医学序贯治疗实现了降期，从而能够切除残留疾病。
